Respiratory Drug Screening Tool
Eliminate false leads earlier-execute continuous flow cell based assays |
|
|
The migration of immune cells to lung tissue induces a hyper-immune response. VenaFlux and Vena8 Biochips from Cellix have been used for the study of asthmatic and allergy conditions. Asthma is caused by a complex interaction of environmental and genetic factors that are not yet fully understand. These factors influence the severity of the patient's asthma and how well they respond to medication. Allergy is a disorder of the immune system resulting in an extreme inflammatory response. Allergic reactions occur to environmental substances known as allergens. Inhaled allergens can also lead to asthmatic symptoms. Cellix's microfluidic Vena8 and VenaEC biochips enable researchers to mimic the inflammatory conditions seen in asthmatic and allergy patients. To learn more about eosinophil adhesion to receptors on the endothelial cell surface and the positive response of drugs for the treatment of asthma (Montelukast) and allergies (Levocetirizine), click on the relevant Application Notes below. |
|
Asthma:Characterising additional anti-inflammatory effects of the anti-asthma drug, Montelukast.
Cellix's VenaFlux platform and Vena8 Biochips were used to determine
novel anti-inflammatory effects of montelukast on resting and GM-CSF
stimulated eosinophils. New drug targets were identified through
eosinophil adhesion to endothelial cell markers.
|
|
Eosinophil rolling and adhesion on lung microvascular endothelial
cells subjected to 0.5 dyne cm² |
Allergy:Anti-histamine effects of Levocetirizine on eosinophil adhesion Eosinophils migrate from blood vessels to surrounding tissue and release histamine. The side effects of the histamine release result in irritation. Cellix provides the ideal solution to study the effectiveness of the non-sedative anti-histamine drug, Levocetirizine. Eosinphil adhesion to markers of the endothelial cell wall is evaluated using Cellix's VenaFlux platform and Vena8 Biochips. |
|